You are here: Industry Insights > Novartis

News List

Novartis recalls liquid version of anemia drug Promacta over risk of contamination from peanut flour fiercepharma
May 15, 2019
Cross-contamination of products is an issue the FDA takes very seriously and will inevitably result in product recall.
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care worldpharmanews
May 15, 2019
Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care.
Novartis to buy Takeda’s dry eye drug Xiidra for $3.4bn pharmaceutical-business-review
May 14, 2019
Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn.
Novartis says it is ready to meet even 'unprecedented' demand for Zolgensma fiercepharma
May 12, 2019
Novartis’ initial jump into gene therapies with pioneering CAR-T drug Kymriah has run into manufacturing challenges that have slowed expansion in the U.S.
Novartis to acquire Xiidra in a $5.3B deal biospectrumasia
May 12, 2019
Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease
Haseeb Ahmad named new ABPI president pharmatimes
May 10, 2019
Haseeb Ahmad named new ABPI president.
Novartis to Acquire Xiidra® americanpharmaceuticalreview
May 10, 2019
Novartis to Acquire Xiidra®
Takeda to divest dry eye drug to Novartis in $5.3bn deal pharmaceutical-technology
May 10, 2019
Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn.
Novartis' blockbuster-to-be Mayzent helps MS patients think faster fiercepharma
May 09, 2019
Novartis’ newly approved multiple sclerosis therapy Mayzent has already shown an ability to cut disability progression and forestall brain shrinkage in patients with the secondary progressive form of the disease (SPMS). Now, it has more data to back its c
Novartis sees Saudi Arabia as promising market for producing its cancer drugs fiercepharma
May 09, 2019
Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore––Saudi Arabia.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page